Delivery Order SPE2DB22D1002-SPE2DB25FLGX8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $9,153.24. This competitively awarded, firm fixed-price contract represents a single delivery order with an ultimate completion date of August 22, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a $33,160.61 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL), with completion targeted for August 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate office and...
- The Defense Logistics Agency awarded a delivery order valued at $20,610.81 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3mL) under a firm fixed price contract. The award was made on July 29, 2025, with an ultimate completion date of July 30, 2025, with performance to take place at the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small individual order within the...
- The Defense Logistics Agency awarded a $27,396.14 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded contract utilizes firm fixed pricing with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,136.92. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as...
- The Defense Logistics Agency awarded a delivery order valued at $16,250.60 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) under a firm fixed price contract. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and represents a non-competitive set-aside delivery order. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,233.87 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $3,919.58 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on July 24, 2025, with a completion date of July 25, 2025. This competitive award was issued under a firm fixed-price contract type with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $7,519.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3 mL) with an ultimate completion date of August 1, 2025. This non-set-aside competitive award was issued on July 31, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $5,995.98 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply delivery under the defense...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLGX8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,852.74 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) under a firm fixed price contract. The award was made on August 27, 2025, with an ultimate completion date of August 28, 2025, and represents a non-set-aside competitive procurement. This delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal procurement portfolio demonstrates extensive capability in delivering specialized medications, including diabetes treatments and other therapeutic products, to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 8/27/25 |